Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.32 |
| ▸ | TET3 | O43151 | 1/20 | 0.32 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445917 | 1.00 | TBXAS1 (0.38) | TBXAS1TET2TET3TET1GRIK1 | |
| SCHEMBL445702 | 1.00 | TBXAS1 (0.38) | TBXAS1TET2TET3TET1GRIK1 | |
| SCHEMBL2358462 | 1.00 | TBXAS1 (0.38) | TBXAS1TET2TET3TET1GRIK1 | |
| SCHEMBL448242 | 1.00 | TBXAS1 (0.38) | TBXAS1TET2TET3TET1GRIK1 | |
| SCHEMBL33514 | 0.98 | TBXAS1 (0.36) | TBXAS1TET2TET3TET1GRIK1 | |
| SCHEMBL15427 | 0.92 | TET2 (0.39) | TBXAS1TET2TET3TET1GRIK1 | |
| Acetone SCHEMBL5519066 | 0.87 | TET2 (0.35) | TBXAS1TET2TET3TET1GRIK1 | |
| SCHEMBL5685778 | 0.85 | CAMK2A (0.35) | TBXAS1TET2TET3TET1GRIK1 | |
| SCHEMBL890544 | 0.84 | TET2 (0.33) | TET2TET3TET1GRIK1GRIK2 | |
| SCHEMBL346413 | 0.84 | TET2 (0.37) | TET2TET3TET1GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307190-B1 | SILICONE-CONTAINING POLYMERIC MATERALS WITH HYDROLYZABLE GROUPS | NOVARTIS AG (CH) | 2015-03-18 | — | — | EP | disclosed |
| US-8883928-B2 | Silicone-containing polymeric materials with hydrolyzable groups | NOVARTIS AG (CH) | 2014-11-11 | — | — | US | disclosed |
| US-20120264963-A1 | PHOTOCURABLE COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-10-18 | — | — | US | disclosed |
| US-8217195-B2 | Photocurable compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-07-10 | — | — | US | disclosed |
| US-20120065331-A1 | SILICONE-CONTAINING POLYMERIC MATERIALS WITH HYDROLYZABLE GROUPS | ALCON INC. (CH) | 2012-03-15 | — | — | US | disclosed |
| US-8079703-B2 | Silicone-containing polymeric materials with hydrolyzable groups | NOVARTIS AG (CH) | 2011-12-20 | — | — | US | disclosed |
| EP-2307190-A1 | SILICONE-CONTAINING POLYMERIC MATERALS WITH HYDROLYZABLE GROUPS | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100197876-A1 | PHOTOCURABLE COMPOUND | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2010-08-05 | — | — | US | disclosed |
| WO-2010011493-A1 | SILICONE-CONTAINING POLYMERIC MATERALS WITH HYDROLYZABLE GROUPS | NOVARTIS AG (CH) | 2010-01-28 | — | — | WO | disclosed |
| US-20100014047-A1 | Silicone-Containing Polymeric Materials with Hydrolyzable Groups | ALCON INC. (CH) | 2010-01-21 | — | — | US | disclosed |
| EP-0181281-B1 | FLUOROALKYLCARBAMYL ACRYLATES AND METHACRYLATES | CIBA-GEIGY AG (CH) | 1989-03-08 | — | — | EP | disclosed |
| EP-0177447-B1 | DIPERFLUOROALKYL CARBAMYL ACRYLATES AND METHACRYLATES | CIBA-GEIGY AG (CH) | 1987-08-19 | — | — | EP | disclosed |
| EP-0181281-A1 | Fluoroalkylcarbamyl acrylates and methacrylates | CIBA-GEIGY AG (CH) | 1986-05-14 | — | — | EP | disclosed |
| EP-0177447-A1 | Diperfluoroalkyl carbamyl acrylates and methacrylates | CIBA-GEIGY AG (CH) | 1986-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264963-A1 | PHOTOCURABLE COMPOUND | ACR, UMPS, UGT1A1 | TBXAS1 2087/4885TET2 107/4885TET3 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.